Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen/Elan Antegren Crohn’s Plans Await Talks With FDA After Trial Fails

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The need for additional studies for Biogen/Elan’s Antegren in Crohn’s disease could hinge upon FDA’s acceptance of data from secondary endpoints or subgroup analysis of the ENACT-1 pivotal trial.

You may also be interested in...



Monoclonal Antibodies For Inflammatory Bowel Disease Prominent At DDW

Many firms involved in bowel disease drug development are seeking to identify subpopulations where new therapies can show activity, late-stage clinical data presented at the Digestive Disease Week meeting in New Orleans May 15-20 indicate.

Elan Antegren Strategy: Separate Crohn’s Maintenance And Induction Claims

Elan/Biogen Idec’s regulatory strategy for gaining approval of Antegren (natalizumab) for Crohn’s disease appears to be centered on separating indications for induction and maintenance therapy.

Elan Antegren Strategy: Separate Crohn’s Maintenance And Induction Claims

Elan/Biogen Idec’s regulatory strategy for gaining approval of Antegren (natalizumab) for Crohn’s disease appears to be centered on separating indications for induction and maintenance therapy.

Related Content

Topics

UsernamePublicRestriction

Register

PS002323

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel